Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced ...
PN-943 (IBD Program) -- Oral, gut-restricted alpha-4-beta-7 integrin antagonist demonstrated greater than threefold improved ...
Takeda Pharmaceutical Company ( ($TAK) ) has provided an announcement. In November 2025, Takeda Pharmaceutical Company announced significant ...
Cash, cash equivalents and marketable securities of $678.8 million as of September 30, 2025, anticipated to provide cash runway through at least end of 2028 NEWARK, CA / ACCESS Newswire / November 6, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback